Real World Patient Characteristics and Treatment Patterns From Crizanlizumab Use: Preliminary Analysis From Select Sickle Cell Centers

Novartis376 enrolled

Overview

This was a retrospective cohort study using secondary data from member sites of the National Alliance of Sickle Cell Centers (NASCC) with patients who had initiated crizanlizumab between 2019 and 2022.

Study Type

OBSERVATIONAL

Enrollment

376

Conditions

Sickle Cell Disease

Eligibility

Sex: ALLMin age: 16 Years

Medical Language ↔ Plain English

Inclusion criteria * Any patient with a diagnosis of SCD based on high performance liquid chromatography (HPLC) or hemoglobin electrophoresis at treating institution. * Treatment order for crizanlizumab; Index date was defined as the date for the first crizanlizumab treatment. * At least 12 months of available electronic medical record (EMR) data pre-index date (baseline). * Patients must have received at least one dose of crizanlizumab. * For inclusion in pre/post analysis of effectiveness, patients must have received crizanlizumab for at least 12 months. Exclusion criteria None identified.

Locations (1)

Novartis Pharmaceuticals

East Hanover, New Jersey, United States

Outcomes

Primary Outcomes

Age at Index Date

Index date was defined as the date of the first crizanlizumab infusion

Time frame: Day 1 of Year 2

Gender at Index Date

Index date was defined as the date of the first crizanlizumab infusion

Time frame: Day 1 of Year 2

Race

Time frame: Day 1 of Year 2

Ethnicity

Time frame: Day 1 of Year 2

Insurance Type at Index Date

Index date was defined as the date of the first crizanlizumab infusion

Time frame: Day 1 of Year 2

Number of Patients Categorized by Comorbidity

Time frame: Baseline

Number of Patients who Received Long-acting Opioid Medication Before Starting Crizanlizumab

Time frame: Baseline

Number of Patients who Received Chronic Red Blood Cell Transfusion Therapy Before Starting Crizanlizumab Categorized by Duration of Therapy

Red blood cell transfusion therapy time intervals: * 0-3 months * 3-6 months * 6-12 months * \>12 months * Unknown

Time frame: Baseline

Number of Patients who Received Chronic Red Blood Cell Transfusion Therapy After Starting Crizanlizumab Categorized by Duration of Therapy

Red blood cell transfusion therapy time intervals: * 0-3 months * 3-6 months * 6-12 months * \>12 months * Unknown

Time frame: Up to 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Secondary Outcomes

Number of Doses Received by Patients Who Continued and Discontinued Crizanlizumab Treatment

Time frame: 1 year

Number of SCD-related Hospitalizations and Emergency Department Visits Pre- and Post-index Date

Index date was defined as the date of the first crizanlizumab infusion.

Time frame: Up to 2 years

Length of Stay of SCD-related Hospitalization Visits Pre- and Post-index Date

Index date was defined as the date of the first crizanlizumab infusion.

Time frame: Up to 2 years